KUWAIT: Minister of Health Dr Ahmad Al-Awadhi issued a ministerial decision Tuesday approving and pricing 392 new drugs, pharmaceutical products and nutritional supplements, selected from 1,580 reviewed over the past year, ensuring they are the cheapest in the Gulf region. In a press statement, the Ministry of Health said the move is part of an integrated strategic approach to balance patient’s interests with the sustainability of the pharmaceutical market.
The strategy involves periodic price list reviews and the adoption of high-quality, effective pharmaceutical alternatives to safeguard public health and maintain the efficiency of healthcare services. The new list includes modern drugs representing a qualitative leap across multiple therapeutic areas, addressing both daily and chronic patient needs. Approved treatments cover obesity, blood pressure, allergies, eye pressure, tumors and cancer, Alzheimer’s disease, migraines, influenza, as well as Mounjaro injections with updated packaging.
The decision also canceled several older drugs that have been replaced with more effective and cost-efficient alternatives. The new pricing system is based on Gulf and international reference prices and is subject to regular review by specialized technical committees monitoring global market developments to maintain price stability. The Ministry stressed that this approach ensures the availability of medicines at affordable prices without compromising quality while preserving the stability of the national pharmaceutical market in both public and private sectors.
The Ministry highlighted that this decision coincides with seven new ministerial directives issued this month to regulate the pharmaceutical sector in line with international standards. These directives aim to streamline medicine registration, ensure adherence to specified prices by companies and distributors, and enhance monitoring mechanisms — both field-based and electronic — to achieve transparency, sustainability and market control. According to the Ministry, the new measures have already contributed to lowering medicine prices and expanding treatment options for patients, within a balanced pharmaceutical policy that considers both efficiency and financial accessibility.
This decision follows a series of recent approvals and price reductions: last August, two decisions were issued reducing prices of 400 medicines and approving 144 new drugs; in May, prices for 69 medicines were approved alongside a reduction in Mounjaro (Tirzepatide) injections; in March, prices for 146 new medicines were approved, preceded by a July 2024 decision reducing prices of more than 200 medicines; and in May 2024, prices for 228 medicines and nutritional supplements were approved. — KUNA